CLINICAL TRIALS PROFILE FOR TAKHZYRO
✉ Email this page to a colleague
All Clinical Trials for TAKHZYRO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04687137 ↗ | Expanded Access Program With Lanadelumab for Japanese People With Hereditary Angioedema | Recruiting | Takeda | Phase 3 | 2021-02-10 | The expanded access program allows people to gain access to an unlicensed treatment on compassionate grounds. Lanadelumab, also known as TAK-743, is a medicine to help prevent hereditary angioedema attacks. Lanadelumab is not yet licensed for use in Japan. The main aim of this study is to allow Japanese teenagers and adults with type I or type II hereditary angioedema to be treated with lanadelumab, through the expanded access program in Japan. Participants can either have taken part in the previous study SHP643-302 or can be new participants. Participants just completing study SHP643-302 who reach the criteria can automatically take part in this study. However, for new participants, the study doctor will check who can take part at the first study visit. For those who can take part, new participants will receive injections of lanadelumab just under the skin. Eventually, after training, some of these will be able to inject themselves with lanadelumab in the same way. Participants who injected themselves with lanadelumab in study SHP643-302 can continue to do so during this study. The study doctors will decide if each participant will be treated with lanadelumab every 2 weeks or every 4 weeks. Treatment with lanadelumab will continue until lanadelumab is commercially available in Japan or the sponsor (Takeda) stops the study. Participants can visit the clinic during treatment if needed. If treatment continues after 6 months, participants will visit the clinic every 12 weeks for a check-up. This will include noting any hereditary angioedema attacks and side effects from the treatment. After 7 months of treatment, the study staff will check-up with each participant every 2 weeks by telephone. After treatment has finished, participants will visit the clinic for a final-check-up 4 weeks later. |
| NCT04848272 ↗ | Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury | Not yet recruiting | St Vincent's Institute of Medical Research | Phase 1 | 2021-04-01 | Phase 1 study investigating safety of lanadelumab administration to patients with lung injury |
| NCT05460325 ↗ | A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) | Recruiting | Takeda | Phase 3 | 2022-06-22 | The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with a subcutaneous injection of lanadelumab every two weeks for 26 weeks. During the study, each participant will make 16 visits to study clinics. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TAKHZYRO
Condition Name
Clinical Trial Locations for TAKHZYRO
Clinical Trial Progress for TAKHZYRO
Clinical Trial Phase
Clinical Trial Sponsors for TAKHZYRO
Sponsor Name
